Outset Medical, Inc. (NASDAQ:OM) Given Average Rating of “Moderate Buy” by Brokerages

Outset Medical, Inc. (NASDAQ:OM) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $10.6667.

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a report on Tuesday, December 16th. Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Royal Bank Of Canada restated a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. Finally, Stifel Nicolaus lowered their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th.

Outset Medical Price Performance

NASDAQ:OM opened at $5.01 on Friday. The firm has a market capitalization of $90.93 million, a price-to-earnings ratio of -0.38 and a beta of 2.07. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The business has a 50 day simple moving average of $4.40 and a 200-day simple moving average of $10.32. Outset Medical has a 1 year low of $3.10 and a 1 year high of $21.98.

Insider Buying and Selling

In other Outset Medical news, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the transaction, the chief executive officer directly owned 107,823 shares in the company, valued at $552,053.76. This trade represents a 9.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Marc Nash sold 5,375 shares of Outset Medical stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $27,520.00. Following the sale, the executive vice president directly owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 35,989 shares of company stock valued at $180,073 over the last quarter. 2.40% of the stock is owned by corporate insiders.

Institutional Trading of Outset Medical

Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in Outset Medical in the second quarter valued at $34,000. Ameritas Investment Partners Inc. purchased a new position in Outset Medical in the 2nd quarter valued at $35,000. BNP Paribas Financial Markets boosted its position in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Outset Medical during the 2nd quarter worth approximately $78,000. Finally, New York State Common Retirement Fund acquired a new position in Outset Medical during the second quarter worth $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.